论文部分内容阅读
近年来乳腺癌新辅助治疗作为标准治疗手段之一愈发受到关注,与辅助治疗相比是否有优势存在的争论也颇多。然而经新辅助化疗达到病理完全缓解(PCR)可以显著改善预后这个不争的事实展示了该治疗方式的美好前景,同时也促使外科医生思考哪类病人能够达到PCR,哪些方案能够使病人从新辅助化疗中最大获益。另外,在治疗过程中运用MRI、循环肿瘤细胞测定等手段对疾病进行监测和疗效预测,使乳腺癌新辅助治疗在安全、可控中进行,做到真正的个体化治疗。
In recent years, neoadjuvant treatment of breast cancer as one of the standard treatment is increasingly concerned about whether there is a competitive advantage compared with adjuvant therapy there are many controversies. However, the indisputable fact that neoadjuvant chemotherapy to achieve pathological complete remission (PCR) can significantly improve the prognosis shows the bright future of this treatment, and also prompts surgeons to think about what kind of patients can achieve PCR, which programs can make patients from neoadjuvant chemotherapy The biggest benefit. In addition, the use of MRI in the course of treatment, circulating tumor cell assays and other means to monitor the disease and predict the efficacy of breast neoadjuvant therapy in a safe, controlled, and truly personalized treatment.